PharmaShots | Incisive News in 3 Shots

Subscribe Now

dupixent

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

October 13, 2020

Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis

Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis

September 14, 2020

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma

September 8, 2020

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

August 19, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us